Surgical outcomes and survival of adrenocortical carcinoma between children and adults


      • Children with adrenocortical carcinoma (ACC) had better survival compared to adults.
      • Increasing age, metastatic disease at diagnosis, and retroperitoneal lymph node dissection are associated with poor survival.
      • Adjuvant chemotherapy and radiation do not impact survival.



      Adrenocortical carcinoma (ACC) is associated with poor outcomes. We compared surgical outcomes between children and adult; and identified factors independently associated with survival.


      Using the National Cancer Database, children and adults with ACC who underwent surgery between 2004 and 2016 were identified. We compared outcomes and survival between groups. Cox regression analysis was performed to identify predictors of survival.


      Of 2553 patients, 2.8% were children. A higher proportion of children were Hispanic (19.1%vs.6.6%) and covered by government insurance (45.1%vs.35.8%) than adults. More pediatric patients received lymphadenectomy and chemotherapy than adults. Pediatric patients had better survival at 1 -(91.4%; 95%CI: 81.2%–96.0% vs.79.6%; 95%CI: 77.9%–81.1%) and 5-years (60.6%; 95%CI:47.5%–71.3% vs.44.9%; 95%CI 42.7%- 47.0) (p = 0.0016). Age≥18 (HR: 2.21(1.50–3.27)), metastatic disease at diagnosis (HR: 3.51(3.04–4.04)), and receipt of lymphadenectomy (HR: 1.30(1.14–1.48)) were independently associated with worse survival.


      Children with ACC had better survival than adults. Factors independently associated with worse survival included older age, metastatic disease, and receipt of lymph node surgery.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Brondani V.B.
        • Fragoso M.
        Pediatric adrenocortical tumor - review and management update.
        Curr Opin Endocrinol Diabetes Obes. 2020 Jun; 27 (PubMed PMID: 32304390. Epub 2020/04/19): 177-186
        • Sharma E.
        • Dahal S.
        • Sharma P.
        • et al.
        The characteristics and trends in adrenocortical carcinoma: a United States population based study.
        J Clin Med Res. 2018 Aug; 10 (PubMed PMID: 29977421. Pubmed Central PMCID: PMC6031252. Epub 2018/07/07): 636-640
        • Else T.
        • Kim A.C.
        • Sabolch A.
        • et al.
        Adrenocortical carcinoma.
        Endocr Rev. 2014 Apr; 35 (PubMed PMID: 24423978. Pubmed Central PMCID: PMC3963263. Epub 2014/01/16): 282-326
        • Gupta N.
        • Rivera M.
        • Novotny P.
        • et al.
        Adrenocortical carcinoma in children: a clinicopathological analysis of 41 patients at the mayo clinic from 1950 to 2017.
        Horm Res Paediatr. 2018; 90 (PubMed PMID: 29804118. Epub 2018/05/29): 8-18
        • Sandrini F.
        • Villani D.P.
        • Tucci S.
        • et al.
        Inheritance of R337H p53 gene mutation in children with sporadic adrenocortical tumor.
        Horm Metab Res. 2005 Apr; 37 (PubMed PMID: 15952083. Epub 2005/06/14): 231-235
        • Rodriguez-Galindo C.
        • Krailo M.D.
        • Pinto E.M.
        • et al.
        Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the children's oncology group ARAR0332 protocol.
        J Clin Oncol. 2021 Aug 1; 39 (PubMed PMID: 33822640. Pubmed Central PMCID: PMC8462560 Accommodations, Expenses: Merck Sharp & Dohme Emilia M. PintoPatents, Royalties, Other Intellectual Property: Genotyping assays to identify mutations in XAF1 pending to St Jude Children's Research Hospital Farzana PashankarConsulting or Advisory Role: Novartis David MalkinConsulting or Advisory Role: Bayer Jonathan D. WassermanConsulting or Advisory Role: Bayer Gerard ZambettiResearch Funding: Johnson & JohnsonPatents, Royalties, Other Intellectual Property: MCL1 antibody license (Rockland Labs) to St Jude Children's Research Hospital. I receive small royalty on an annual basis, Patent pending for Genotyping assays to identify mutations in XAF1 Provisional application #62/659,427; Foreign filing April 18, 2019 Alberto S. PappoHonoraria: Bayer, RocheConsulting or Advisory Role: Merck, Loxo/Bayer, EUSA Pharma, DebbioNo other potential conflicts of interest were reported. Epub 2021/04/07): 2463-2473
        • Varghese J.
        • Habra M.A.
        Update on adrenocortical carcinoma management and future directions.
        Curr Opin Endocrinol Diabetes Obes. 2017 Jun; 24 (PubMed PMID: 28277340. Epub 2017/03/10): 208-214
        • Zekri W.
        • Hammad M.
        • Rashed W.M.
        • et al.
        The outcome of childhood adrenocortical carcinoma in Egypt: a model from developing countries.
        Pediatr Hematol Oncol. 2020 Apr; 37 (PubMed PMID: 31971470. Epub 2020/01/24): 198-210
        • Gulack B.C.
        • Rialon K.L.
        • Englum B.R.
        • et al.
        Factors associated with survival in pediatric adrenocortical carcinoma: an analysis of the National Cancer Data Base (NCDB).
        J Pediatr Surg. 2016 Jan; 51 (PubMed PMID: 26572849. Pubmed Central PMCID: PMC5131646. Epub 2015/11/18): 172-177
        • Sabaretnam M.
        • Mishra A.
        • Agarwal G.
        • et al.
        Adrenocortical carcinoma in children and adults: two decades experience in a single institution.
        Indian J Cancer. 2016 Apr-Jun; 53 (PubMed PMID: 28071637. Epub 2017/01/11): 317-321
        • Tella S.H.
        • Kommalapati A.
        • Yaturu S.
        • Kebebew E.
        Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database.
        J Clin Endocrinol Metab. 2018 Sep 1; 103 (PubMed PMID: 29982685. Epub 2018/07/10): 3566-3573
        • American College of Surgeons
        National Cancer Database.
        2022 ([cited 2021 December 15 ])
        • Faria A.M.
        • Almeida M.Q.
        Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults.
        Mol Cell Endocrinol. 2012 Mar 31; 351 (PubMed PMID: 22019901. Epub 2011/10/25): 52-57
        • Rodriguez-Galindo C.
        • Figueiredo B.C.
        • Zambetti G.P.
        • Ribeiro R.C.
        Biology, clinical characteristics, and management of adrenocortical tumors in children.
        Pediatr Blood Cancer. 2005 Sep; 45 (PubMed PMID: 15747338. Epub 2005/03/05): 265-273
        • Ayala-Ramirez M.
        • Jasim S.
        • Feng L.
        • et al.
        Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.
        Eur J Endocrinol. 2013 Dec; 169 (PubMed PMID: 24086089. Pubmed Central PMCID: PMC4441210. Epub 2013/10/03): 891-899
        • McAteer J.P.
        • Huaco J.A.
        • Gow K.W.
        Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study.
        J Pediatr Surg. 2013 May; 48 (PubMed PMID: 23701777. Epub 2013/05/25): 1025-1031
        • Kerkhofs T.M.
        • Ettaieb M.H.
        • Verhoeven R.H.
        • et al.
        Adrenocortical carcinoma in children: first population-based clinicopathological study with long-term follow-up.
        Oncol Rep. 2014 Dec; 32 (PubMed PMID: 25241764. Epub 2014/09/23): 2836-2844
        • Gharzai L.A.
        • Green M.D.
        • Griffith K.A.
        • et al.
        Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma.
        J Clin Endocrinol Metab. 2019 Sep 1; 104 (PubMed PMID: 31220287. Epub 2019/06/21): 3743-3750